Robertson Stephens Wealth Management LLC Buys Shares of 12,539 Zimmer Biomet Holdings, Inc. $ZBH

Robertson Stephens Wealth Management LLC bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 12,539 shares of the medical equipment provider's stock, valued at approximately $1,131,000.

A number of other hedge funds have also modified their holdings of ZBH. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter worth $204,000. Sivia Capital Partners LLC acquired a new position in shares of Zimmer Biomet in the second quarter worth $232,000. United Bank increased its stake in shares of Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider's stock worth $1,085,000 after acquiring an additional 1,153 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of Zimmer Biomet by 129.2% in the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider's stock worth $194,000 after acquiring an additional 1,202 shares during the last quarter. Finally, Cerity Partners LLC increased its stake in shares of Zimmer Biomet by 93.6% in the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider's stock worth $7,004,000 after acquiring an additional 37,116 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 0.2%

Zimmer Biomet stock opened at $83.07 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The company has a market capitalization of $16.08 billion, a price-to-earnings ratio of 21.58, a PEG ratio of 1.91 and a beta of 0.48. Zimmer Biomet Holdings, Inc. has a one year low of $79.83 and a one year high of $108.29. The company's fifty day moving average price is $92.53 and its two-hundred day moving average price is $92.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business's quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Zimmer Biomet's dividend payout ratio is presently 24.94%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Sanford C. Bernstein upped their price target on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a "market perform" rating in a research note on Friday, January 9th. Barclays dropped their price target on shares of Zimmer Biomet from $100.00 to $94.00 and set an "underweight" rating on the stock in a research note on Wednesday. Leerink Partners assumed coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They issued a "hold" rating and a $101.00 price target on the stock. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research note on Wednesday. Finally, Weiss Ratings raised shares of Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $102.43.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company's stock, valued at $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.28% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.